The Amyloidosis Forum
Accelerating the development of new approaches to advance innovation in amyloidosis
The Amyloidosis Forum, formed in 2019, is a public-private partnership between the Amyloidosis Research Consortium (ARC) and the U.S. Food and Drug Administration (FDA). The overarching goal of the Forum is to accelerate the advancement of new therapeutics by addressing scientific gaps and unmet research needs in the precompetitive domain that aid in the evaluation of the efficacy and safety of new therapies.
The Amyloidosis Forum creates a unique environment to foster cross-disciplinary and cross-stakeholder collaboration between academia, industry, regulators and other partners to optimize innovation. The Forum gathers experts together to build workstreams that focus on key areas of research or shared interest to collectively move the field forward.